Phase III Success For Roche’s Crovalimab In Crowded PNH Market
But AstraZeneca Expected To Retain Grip In The Space
Roche is looking to challenge AstraZeneca's dominance in PNH with its subcutaneously administered once-a-month treatment but could struggle to rival the company's and Novartis’s oral therapy.
